Physician profile
Kiel J Pfefferle
NPI 1063723765
$64,893.10
in general payments reported to CMS, 2019-2025
8 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $211 · 2021: $11K · 2022: $14K · 2023: $17K · 2024: $8,065 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Travel and Lodging: $2,614 · Food and Beverage: $1,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,488.19 |
| Travel and Lodging | $2,614.10 |
| Food and Beverage | $1,293.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $53,177.61 | 2019-2024 | Actis, Summit, Attune |
| Depuy Synthes Products, INC. | $7,973.79 | 2023-2024 | Actis, Attune, Pinnacle |
| Depuy Synthes Sales INC. | $1,934.05 | 2019-2024 | Velys, Actis |
| Stryker Corporation | $1,529.28 | 2025 | Mako, Insignia, Triathlon |
| Medacta USA, INC. | $142.40 | 2023 | Gmk Sphere |
| Smith+Nephew, INC. | $65.92 | 2020 | |
| Orthalign INC | $49.33 | 2025 | Orthalign Plus |
| Vertex Pharmaceuticals Incorporated | $20.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiel Pfefferle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.